Insulet Co. (NASDAQ:PODD) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 8.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,432 shares of the medical instruments supplier’s stock after selling 425 shares during the period. Securian Asset Management Inc.’s holdings in Insulet were worth $962,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Baillie Gifford & Co. acquired a new position in shares of Insulet in the fourth quarter worth $263,144,000. William Blair Investment Management LLC raised its stake in Insulet by 145.1% in the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock valued at $116,894,000 after buying an additional 433,884 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in Insulet by 227.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock worth $61,673,000 after buying an additional 268,553 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Insulet by 62.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 637,261 shares of the medical instruments supplier’s stock worth $101,637,000 after acquiring an additional 244,922 shares in the last quarter. Finally, Artisan Partners Limited Partnership purchased a new position in shares of Insulet in the 3rd quarter valued at about $29,455,000.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on PODD shares. Stifel Nicolaus increased their price target on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Jefferies Financial Group boosted their target price on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Canaccord Genuity Group increased their price target on Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research note on Tuesday, May 7th. Finally, Piper Sandler lowered their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $239.44.

Insulet Trading Down 0.7 %

Shares of PODD opened at $182.79 on Wednesday. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $309.72. The stock has a market cap of $12.80 billion, a price-to-earnings ratio of 55.39, a price-to-earnings-growth ratio of 3.31 and a beta of 1.00. The firm has a 50 day simple moving average of $171.28 and a 200-day simple moving average of $184.33.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to analysts’ expectations of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.23 earnings per share. Equities analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.